Technical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma
NEW YORK, September 20, 2017 /PRNewswire/ --
If you want a Stock Review on VNDA, ACAD, ACHN, or AGIO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com monitors Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). These stocks belong to the Biotechnology space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:
http://dailystocktracker.com/register/
Vanda Pharmaceuticals
On Tuesday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. rose 0.82%, ending the day at $18.35. The stock recorded a trading volume of 586,110 shares, which was above its three months average volume of 535,490 shares. The Company's shares have advanced 15.41% in the last one month, 20.72% over the previous three months, and 15.05% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.59% and 21.72%, respectively. Moreover, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have a Relative Strength Index (RSI) of 69.47.
On September 13th, 2017, Vanda Pharma announced results from an eight-week randomized Phase-II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity.
On September 14th, 2017, research firm Piper Jaffray reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $23 a share to $26 a share. VNDA complete research report is just a click away at:
http://dailystocktracker.com/registration/?symbol=VNDA
ACADIA Pharmaceuticals
Shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. ended the day 1.16% lower at $36.55 with a total trading volume of 836,769 shares. In the last month and the previous three months, the stock has gained 17.60% and 29.52%, respectively. Additionally, the Company's shares have advanced 26.73% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.51% and 15.12%, respectively. Furthermore, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI of 63.88. The complimentary report on ACAD can be downloaded at:
http://dailystocktracker.com/registration/?symbol=ACAD
Achillion Pharmaceuticals
At the close of trading on Tuesday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. finished 3.21% higher at $3.86 with a total trading volume of 1.30 million shares. The stock is trading below its 200-day moving average by 8.08%. Shares of the Company, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 37.08.
On September 11th, 2017, Achillion Pharma announced that Executive Vice President Joseph Truitt has been promoted to COO, a new position within the Company. The Company also announced the appointment of Avner Ingerman, M.D. as Senior Vice President and Head of Ophthalmology, also a newly created position.
On September 12th, 2017, research firm Ladenburg Thalmann reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $9 a share to $6.50 a share. Sign up for your complimentary research report on ACHN at:
http://dailystocktracker.com/registration/?symbol=ACHN
Agios Pharmaceuticals
Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc.'s shares recorded a trading volume of 322,503 shares at the end of yesterday's session. The stock closed the day 1.56% lower at $65.82. The Company's shares have surged 19.48% in the past month, 24.78% in the previous three months, and 57.73% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.65% and 26.74%, respectively. Additionally, shares of Agios Pharma, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 63.45.
On September 15th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $78 per share. Get free access to your research report on AGIO at:
http://dailystocktracker.com/registration/?symbol=AGIO
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
